USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center

USC-UCLA 药物性肝损伤 (DILI) 临床中心

• 批准号: 10731578
• 负责人: ANDREW Abba STOLZ
• 金额: $ 36.28万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10731578
• 关键词: Acute; Ancillary Study; Assessment tool; Cell Death; Cholestasis; Clinical Treatment; Collection; County; Data Coordinating Center; Databases; Development; Endoplasmic Reticulum; Enrollment; Etiology; Event; Future; Herbal supplement; Immune; Immune checkpoint inhibitor; Knowledge; Los Angeles; Mediating; Medicine; Mitochondria; Natural Immunity; Patients; Pharmaceutical Preparations; Pilot Projects; Plant Preparations; Population Heterogeneity; Proteins; Protocols documentation; Research Personnel; Resources; Role; Scientific Advances and Accomplishments; Talents; Underrepresented Populations; United States; United States National Institutes of Health; Vitamins; Work; acute liver injury; clinical center; dietary supplements; drug induced liver injury; ethnic diversity; follow-up; hepatocellular injury; inhibitor; liver injury; medical schools; novel; patient population; pharmacovigilance; phase 2 study; preservation; research clinical testing; response; shared database; treatment trial

The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) proposal in response to RFA-DK-22-013 “Continuation of the Drug Induced Liver Injury Network (DILIN) Clinical Centers” hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our proposal will continue to combine the only two medical schools in Los Angeles County allowing us to be able to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.8 M residents of Los Angeles County (2022) are an unmatched resource composed of the most ethnically diverse population in the United States. Our proposal continues to utilize the expertise and talents from Keck School of Medicine of USC and David Geffen School of Medicine at UCLA. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC’s ability to capture DILIN cases in this diverse populations with little overlap in etiology for DILI other than for herbal and dietary supplements (HDS) in our respective patient populations. The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continued enrollment of high quality bona fide DILI case from under represented populations and HDS agents with proposed biospecimens collections for future studies.; 2) Specific Aim 2: Mechanism of cell death and the role of innate immunity in Immune-Mediated Liver Injury due to Checkpoint Inhibitors (ILICI) (Ancillary Study); 3) Specific Aim 3: Proposed Clinical Treatment Trial for Cholestatic and Acute Liver Injury and 4) Specific Aim 4: Continued support of the DILIN’s effort to develop causality assessment instruments and development of a pilot project for a pharmacovigilance protocol for adverse liver injury due to medication or HDS. .

响应RFA-DK-22-013 “药物诱发肝损伤网络（Dilin）临床中心的延续”希望继续参与 与其他CC一起推进了DILI的科学知识和临床评估。我们的建议将继续 结合洛杉矶县仅有的两所医学院，使我们能够唯一捕获和 将DILI案例注册到由数据协调中心（DCC）监督的网络数据库中。 9.8 m 洛杉矶县（2022）的居民是一种由种族最多的潜水员组成的无与伦比的资源 在美国的人口。我们的建议继续利用凯克学校的专业知识和才能 UCLA的USC和David Geffen医学院的医学。大量善意的注册 经过紧密随访的患病患者表明了我们CC在该潜水员中捕获稀释病例的能力 除了草药和饮食补充剂（HDS）以外，DILI的病因学很少有重叠的人群（HDS） USC-UCLA DILI CC继续进行的具体目的是：1） 从代表人群和HDS代理人持续入学高质量的真正的善意案件 提议的生物测量收集供未来的研究。 2）特定目标2：细胞死亡的机理和 先天免疫在检查点抑制剂（ILICI）引起的免疫介导的肝损伤中的作用（辅助研究）； 3） 特定目的3：提议的胆固醇和急性肝损伤的临床治疗试验，4）特定目标4： 持续支持迪林（Dilin 由于药物或HDS导致的不良肝损伤的药物守护程序计划。 。

项目成果

HLA-B*53:01 Is a Significant Risk Factor of Liver Injury due to Phenytoin and Other Antiepileptic Drugs in African Americans.

HLA-B*53:01 是非裔美国人因苯妥英和其他抗癫痫药物导致肝损伤的重要危险因素。

• DOI: 10.14309/ajg.0000000000002454
• 发表时间: 2024
• 期刊: The American journal of gastroenterology
• 作者: Nicoletti,Paola;Dellinger,Andrew;Li,Yi-Ju;Barnhart,Huiman;Phillips,Elizabeth;Chalasani,Naga;DrugInducedLiverInjuryNetwork(DILIN)investigators
• 通讯作者: DrugInducedLiverInjuryNetwork(DILIN)investigators

Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.

• DOI: 10.1111/liv.15189
• 发表时间: 2022-06
• 期刊: LIVER INTERNATIONAL
• 影响因子: 6.7
• 作者: Devarbhavi, Harshad;Ghabril, Marwan;Barnhart, Huiman;Patil, Mallikarjun;Raj, Sujata;Gu, Jiezhun;Chalasani, Naga;Bonkovsky, Herbert L.
• 通讯作者: Bonkovsky, Herbert L.

Ashwagandha-induced liver injury: A case series from Iceland and the US Drug-Induced Liver Injury Network.

• DOI: 10.1111/liv.14393
• 发表时间: 2020-04
• 期刊: Liver international : official journal of the International Association for the Study of the Liver
• 作者: Björnsson HK;Björnsson ES;Avula B;Khan IA;Jonasson JG;Ghabril M;Hayashi PH;Navarro V
• 通讯作者: Navarro V

Value of liver biopsy in the diagnosis of drug-induced liver injury.

• DOI: 10.1016/j.jhep.2021.12.043
• 发表时间: 2022-05
• 期刊: JOURNAL OF HEPATOLOGY
• 影响因子: 25.7
• 作者: Ahmad, Jawad;Barnhart, Huiman X.;Bonacini, Maurizio;Ghabril, Marwan;Hayashi, Paul H.;Odin, Joseph A.;Rockey, Don C.;Rossi, Simona;Serrano, Jose;Tillmann, Hans L.;Kleiner, David E.
• 通讯作者: Kleiner, David E.

Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury.

• DOI: 10.1111/liv.13380
• 发表时间: 2017-11
• 期刊: Liver international : official journal of the International Association for the Study of the Liver
• 作者: Suzuki A;Barnhart H;Gu J;Bonkovsky HL;Tillmann HL;Fontana RJ;Kleiner DE;Drug-induced Liver Injury Network (DILIN)
• 通讯作者: Drug-induced Liver Injury Network (DILIN)